Core Viewpoint - Fosun Pharma is planning to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Structure - Fosun Pharma's subsidiary, Fosun Pharma Industry, and partners intend to establish a special fund with a target capital of RMB 547 million, with contributions from various parties [2] - The fund will be structured with Fosun Pharma Industry contributing RMB 54.6 million, while Zhonghui Life will contribute RMB 491.4 million, resulting in respective ownership stakes of 9.98% and 89.84% [2] - Following the establishment of the fund, Fosun Pharma Industry will transfer 100% equity of Shanghai Clone for a consideration not exceeding RMB 1.256 billion [2] Group 2: Asset Details - The main asset of Shanghai Clone includes state-owned land use rights and property ownership located at 1289 Yishan Road, Xuhui District, Shanghai, covering an area of 19,944 square meters with a building area of 45,238.55 square meters [2] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operational purposes [3] - Shanghai Fushun, a subsidiary, will provide asset management services for Shanghai Clone post-transfer [3]